scholarly journals Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease

2020 ◽  
Vol 3 (2) ◽  
pp. 98-99
Author(s):  
Paul Moayyedi ◽  
Eric I Benchimol ◽  
David Armstrong ◽  
Cathy Yuan ◽  
Aida Fernandes ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Position Statement ◽  
Inflammatory Bowel

Turkish IBD Organization’s Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic

2021 ◽  
Vol 32 (6) ◽  
pp. 488-492
Author(s):  
Murat Toruner ◽  
◽  
Ismail Hakki Kalkan ◽  
Filiz Akyuz ◽  
Ahmet Tezel ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Management ◽  
Bowel Disease ◽  
Position Statement ◽  
Inflammatory Bowel ◽  
Management Recommendations

scholarly journals ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update

2016 ◽  
Vol 11 (1) ◽  
pp. 26-34 ◽  
Author(s):  
Silvio Danese ◽  
Gionata Fiorino ◽  
Tim Raine ◽  
Marc Ferrante ◽  
Karen Kemp ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Position Statement ◽  
Inflammatory Bowel

scholarly journals Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

2019 ◽  
Vol 14 (5) ◽  
pp. 680-685 ◽  
Author(s):  
Michaël Somers ◽  
Peter Bossuyt ◽  
Marc Ferrante ◽  
Harald Peeters ◽  
Filip Baert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Research Group ◽  
Bowel Disease ◽  
Inflammatory Diseases ◽  
Safety Data ◽  
Position Statement ◽  
European Medicines Agency ◽  
Immune Mediated ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract The emergence of biosimilars is generally considered as an opportunity to guarantee accessibility to affordable treatments and to enhance financial sustainability of national health systems. Since 2017, five biosimilars of adalimumab were approved by the European Medicines Agency [EMA] for use in inflammatory bowel disease: ABP 510, SB5, GP2017, FKB327, and MSB11022. In this position statement, the available efficacy and safety data of the different adalimumab biosimilars in immune-mediated inflammatory diseases are summarised. Furthermore, the Belgian IBD research group [BIRD] formulates statements concerning the use of adalimumab biosimilars in inflammatory bowel disease.

Sign in / Sign up

Export Citation Format

Share Document